Examples of using Seroconversion in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
20, seroconversion rate and seroconversion factor as measured by microneutralisation assay(MN)
In the study in HBeAg positive patients, HBeAg seroconversion(12%) and HBeAg loss(24%)
U ispitivanju u HBeAg pozitivnih pacijenata, serokonverzija HBeAg(12%) te nestanak HBeAg(24%)After primary vaccination the rate of subjects with neutralising antibody titres≥ 20, seroconversion rate and seroconversion factor as measured by microneutralisation assay(MN)
Nakon prvog cijepljenja, stopa ispitanika s titrom neutralizirajućih protutijela ≥ 20, stopa serokonverzije i čimbenik serokonverzije izmjereni mikroneutralizacijskom analizom(MN)However, the proportions of subjects who achieved HBeAg seroconversion at week 48 were similar(11%)
Međutim, udio ispitanika koji su postigli serokonverziju HBeAg u 48. tjednu bio je sličan(11%)After primary vaccination the seroprotection rate, seroconversion rate and seroconversion factor for anti-HA antibody as measured by single radial haemolysis(SRH)
Nakon prvog cijepljenja, stopa serozaštite, serokonverzije i čimbenik serokonverzije za anti-HA antitijela izmjereni jednosmjernom radijalnom hemolizom(engl.39% achieved HBeAg seroconversion, 90% achieved ALT normalisation at week 52
39% je postiglo HBeAg serokonverziju, 90% je postiglo normalizaciju ALT-a u 52. tjednu,HBeAg loss and seroconversion.
nestankom HBeAg i serokonverzijom.After vaccination the seroprotection rate, seroconversion rate and seroconversion factor for anti-HA antibody as measured by single radial haemolysis(SRH)
Nakon cijepljenja stopa serozaštite, serokonverzije i čimbenik serokonverzije za anti-HA protutijela izmjereni jednosmjernom radijalnom hemolizom(SRH)sustained HBeAg seroconversion 79.2%; 19/24.
i održivu HBeAg serokonverziju 79,2%; 19/24.abnormal baseline ALT and none achieved HBeAg seroconversion.
jedan bolesnik nije postigao HBeAg serokonverziju.Table 10: Seroconversion rates, rates of subjects with at least 4-fold increase in JEV neutralizing antibody titers
Tablica 10 Stope serokonverzije, udio ispitanika s najmanje četverostrukim porastom titra neutralizirajućih protutijela na virus JETable 5: Seroconversion rates and GMTs for anti-JEV neutralizing antibodies on Day 0,
Tablica 5: Stope serokonverzije i geometrijske sredine titra(GMT) neutralizirajućih anti-JEV protutijela na 0.,The difference in the HBeAg seroconversion rates(HBeAg and HBV DNA loss with HBeAb detection)
Razlika u stopama serokonverzije(gubitak HbeAg i HBV DNK uz detekciju HbeAb)seroprotection rates, seroconversion rates and serconversion factors(compared to pre-booster antibody levels)
stupnjevi serokonverzije i čimbenici serokonverzije(u usporedbi s razinama protutijela prije boostera)In HBeAg positive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion(HBeAg loss and HBV DNA loss with anti-HBe detection) is confirmed or until HBs seroconversion or there is loss of efficacy see section 4.4.
Kod HBeAg pozitivnih pacijenata bez ciroze, liječenje se mora primjenjivati najmanje 6 do 12 mjeseci nakon HBe serokonverzije(nestanak HBeAg i HBV DNK s detekcijom anti-HBe) ili sve do HBs serokonverzije ili do gubitka djelotvornosti vidjeti dio 4.4.Telbivudine-treated patients who achieved undetectable HBV DNA by PCR by week 24 had the highest rates of HBV DNA undetectability and HBeAg seroconversion(in HBeAg-positive patients), and the lowest overall
Bolesnici liječeni telbivudinom koji su postigli nemjerljiv HBV DNK metodom PCR 24. tjednu su imali najviše stope nemjerljivog HBV DNK i HBeAg serokonverzije(u HBeAg-pozitivnih bolesnika)HAV antibody, and for seroconversion rates of both antibody types Table 7.
HAV protutijela i obzirom na stope serokonverzije oba tipa protutijela Tablica 7.the study population and included the determination of the seroconversion rate(SCR), defined as JEV neutralizing antibody titer≥1:10,
uključivala je određivanje stope serokonverzije(SCR), definirane kao titar neutralizirajućih protutijela na virus JE ≥1:10,The seroprotection rate and seroconversion rate measured by HI assay and the seroconversion factor expressed as geometric mean ratio of HI for anti-HA antibody to H1N1 after administration of one
Stupanj serozaštite, stupanj serokonverzije izmjereni HI testom i čimbenik serokonverzije izražen kao koeficijent geometrijske sredine HI za anti-HA protutijelo na H1N1 nakon primjene jedne ili dviju doza od 7,While DAGT seroconversion in patients receiving Zavicefta was very common in clinical studies(the estimated range of seroconversion across Phase 3 studies was 3.2% to 20.8% in patients with a negative Coombs test at baseline and at least one follow-up test),
Iako je serokonverzija dokazana DAGT-om kod bolesnika koji su primali lijek Zavicefta bila vrlo česta u kliničkim ispitivanjima(procijenjeni raspon 
